Myriad Genetics (MYGN) Change in Account Payables (2016 - 2026)
Myriad Genetics has reported Change in Account Payables over the past 17 years, most recently at -$4.2 million for Q4 2025.
- Quarterly Change in Account Payables fell 281.82% to -$4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, down 129.79% year-over-year, with the annual reading at -$1.4 million for FY2025, 129.79% down from the prior year.
- Change in Account Payables was -$4.2 million for Q4 2025 at Myriad Genetics, down from -$800000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $14.0 million in Q4 2021 and troughed at -$12.9 million in Q3 2021.
- The 5-year median for Change in Account Payables is -$800000.0 (2025), against an average of $278947.4.
- Year-over-year, Change in Account Payables soared 1266.67% in 2021 and then plummeted 1166.67% in 2022.
- A 5-year view of Change in Account Payables shows it stood at $14.0 million in 2021, then crashed by 117.14% to -$2.4 million in 2022, then plummeted by 145.83% to -$5.9 million in 2023, then surged by 81.36% to -$1.1 million in 2024, then plummeted by 281.82% to -$4.2 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Change in Account Payables are -$4.2 million (Q4 2025), -$800000.0 (Q3 2025), and $3.6 million (Q2 2025).